By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


H. Lundbeck A/S 

Ottiliavej 9

Valby  Copenhagen  DK-2500  Denmark
Phone: 45-3630-1311 Fax: 45 3630 1940



Forest  Forest's partner for many of the drug compounds that we develop, manufacture and market in the U.S. for central nervous system disorders, including Lexapro.

Company News
H. Lundbeck A/S (LUN.CO) And Takeda (TKPYY) Receive Complete Response Letter From The FDA For Trintellix (Vortioxetine) Snda 6/23/2017 11:05:17 AM
H. Lundbeck A/S (LUN.CO) Obtains Rights To Breakthrough Research In Alzheimer’s Disease 6/6/2017 8:45:12 AM
Transactions With Shares And Linked Securities In H. Lundbeck A/S (LUN.CO) Made By Executives And Their Closely Associated Parties 5/24/2017 10:13:02 AM
H. Lundbeck A/S (LUN.CO) Release: 2017 Guidance Raised Based On Strong Revenue Growth And Improved Profitability 5/10/2017 11:04:40 AM
H. Lundbeck A/S (LUN.CO) Gets $55.6 Million From Sale Of Part Of Its HQ 5/5/2017 6:09:29 AM
H. Lundbeck A/S (LUN.CO) Throws in the Towel on Alzheimer's Pill, Giving Leeway to Rival Axovant (AXON) 2/8/2017 5:27:55 AM
Ossianix Release: Company Receives Milestone Payment From H. Lundbeck A/S (LUN.CO) For Blood-Brain Barrier (BBB) Antibody Delivery Technology 1/26/2017 9:18:24 AM
Otsuka Pharmaceutical Development & Commercialization, Inc. And H. Lundbeck A/S (LUN.CO) Present Data At ACNP Annual Meeting On Long-Acting Injectable Aripiprazole As A Potential Maintenance Treatment For Bipolar I Disorder 12/7/2016 9:46:21 AM
H. Lundbeck A/S (LUN.CO)'s Phase III Data Crushes Hope for Alzheimer’s Once Again 9/23/2016 5:45:12 AM
Patient Groups Rank Lundbeck US First In Corporate Reputation Among Top Pharmaceutical Companies 4/7/2016 11:27:42 AM